Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.03 ▼ -0.01
(-0.96%)
MKT CAP: $260.5M • VOL: 937.7K
52W L $1 52W H $2
LCTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $14.6M | $9.5M | $8.9M |
| YoY Revenue Growth % | +53.2% | +6.2% | — |
| Gross Profit | — | $9.2M | — |
| Gross Margin % | — | 96.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.6M | -$21.5M | -$24.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$63.5M | -$18.6M | -$21.5M |
| EBITDA (Normalized) | -$36.2M | -$21.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.9M | -$23.1M | -$28.6M |
| Capital Expenditures (CapEx) | $522.0K | $565.0K | — |
| Free Cash Flow (FCF) | -$19.4M | -$23.7M | -$28.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $40.8M | $45.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $44.5M | $78.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LCTX.